Otsuka zips into adjuvant use
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
Otsuka bids for a seat at the conjugate table
The acquisition of Araris follows a 2023 discovery collaboration.
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
The acquisition of Araris follows a 2023 discovery collaboration.
